Alligator Bioscience Advances Mitazalimab with Successful Phase 3 Manufacturing

Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an announcement.

Alligator Bioscience has successfully completed the manufacturing of the first GMP drug product batch of mitazalimab, its lead asset, using an improved commercial-scale process. This milestone supports the readiness for a Phase 3 trial targeting first-line metastatic pancreatic cancer, marking a significant advancement in the drug’s development and reducing associated risks. The production was carried out by Thermo Fisher Scientific, underscoring Alligator’s commitment to delivering new treatment options for pancreatic cancer in collaboration with future partners.

More about Alligator Bioscience AB

Alligator Bioscience is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of tumor-directed immuno-oncology antibody drugs. The company focuses on the CD40 receptor to enhance the priming of tumor-specific T cells and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients across various cancer types. Alligator’s lead drug candidate, mitazalimab, is preparing for Phase 3 development following promising survival data in previous trials.

Average Trading Volume: 191,019

Current Market Cap: SEK66.54M

See more data about ATORX stock on TipRanks’ Stock Analysis page.